Dermatology, Portfolios and Safety - Esthetician Leadership Today

U.S. FDA Approves Celltrion’s STELARA Biosimilar

The Dermatology Digest

DECEMBER 18, 2024

The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. “STEQEYMA is now the latest biologic in our immunology portfolio, joining ZYMFENTRA (infliximab-dyyb). . immunology market.”

Portfolios

Portfolios Injections Office Safety

FDA Nod for PYZCHIVA (ustekinumab-ttwe), Samsung Bioepis’ Stelara Biosimilar

The Dermatology Digest

JULY 1, 2024

The FDA’s approval of PYZCHIVA is based on a totality of evidence including analytical, non-clinical and clinical data demonstrating biosimilarity to Stelara, with no clinically meaningful differences in terms of safety, purity and potency. PYZCHIVA, developed by Samsung Bioepis, will be commercialized by Sandoz in the United States.

Portfolios

Portfolios Safety Clinic Injections

PHysicians & the esthetician

Southeastern Esthetics Institute

AUGUST 23, 2016

Specific courses for cosmetic lasers, for example, are crucial to add to the esthetics portfolio, in order to showcase added training beyond that of the esthetics fundamentals course. Esthetics practitioners within any advanced setting should obtain certifications underneath their license for each individual advanced procedure.

Esthetician

Esthetician Esthetics Document Office

FDA Approves JUVÉDERM VOLUMA XC for Filling Temple Hollows

The Dermatology Digest

MARCH 5, 2024

The Allergan Medical Institute (AMI) team can train aesthetic providers on safe and effective treatments using the Allergan Aesthetics portfolio to address 90% of the face. The post FDA Approves JUVÉDERM VOLUMA XC for Filling Temple Hollows appeared first on The Dermatology Digest.

Portfolios

Portfolios Injections Training Facials

TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology in the U.S. and Abroad

The Dermatology Digest

SEPTEMBER 9, 2024

“China has always been a strategic market for Sisram, and the approval of Daxxify serves as a key milestone for bringing Sisram’s high-end injectables portfolio to Mainland China,” says Mr. Liu Yi, Sisram Chairman and Executive Director, in a news release. and Abroad appeared first on The Dermatology Digest.

Portfolios

Portfolios Dermatology Injections Marketing

FDA Nod for Ustekinumab Biosimilar

The Dermatology Digest

SEPTEMBER 30, 2024

market, is an important milestone on our pathway to consistently broadening our biopharma portfolio in the U.S. Otulfi demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to Stelara in patients with moderate to severe psoriasis vulgaris. and worldwide.

Portfolios

Portfolios Partnerships Marketing Safety

Topline Phase 1 Trial Results for Apogee’s APG777 in AD “Exceed Expectations”

The Dermatology Digest

MARCH 5, 2024

The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate the safety and PK of APG777 in healthy volunteers. The study enrolled 40 healthy adult participants into three single-ascending dose (SAD) and two multiple-ascending dose (MAD) cohorts.

Injections

Injections Safety Sustainability Clinic

Sunscreen E-Summit 2022: Replay

The Eco Well Blog

MAY 16, 2022

Next up, we’ll be tackling the topic of safety, coming your way in late September. serves as Environmental Scientist at Personal Care Products Council (PCPC) and focuses on assessing the environmental safety of cosmetics and personal care ingredients. This was our attempt to democratize accurate information for the cosmetics industry.

Legal

Legal Pharmaceutical Sun Protection Technology

2023 Sunscreen E-Summit Replay

The Eco Well Blog

MAY 8, 2023

She is also an adjunct professor in the Department of Dermatology at the Keck School of Medicine of the University of Southern California. Her area of clinical expertise is in complex medical dermatology, skin cancer, and acne. Carl presented at the Sunscreen E-Summit on behalf of DSM.

Legal

Legal Technology Sun Protection Branding

FDA OKs Emergent’s mPox Vaccine

The Dermatology Digest

AUGUST 30, 2024

The approval is based on previously available human safety data and data from a well-controlled animal study in which ACAM2000 vaccine was shown to be effective in protecting against mpox virus exposure. The post FDA OKs Emergent’s mPox Vaccine appeared first on The Dermatology Digest.

Portfolios

Portfolios Tools Eczema Safety

Evolus Scores EU Approval of Estyme Injectable Hyaluronic Acid Gel Fillers Under New Medical Device Regulation Process

The Dermatology Digest

NOVEMBER 4, 2024

The EU Medical Device Regulation (MDR) certification gave its nod to four injectable hyaluronic acid (HA) gel fillers from Evolus under the brand name Estyme, The CE Mark certification, through the new MDR process, represents more stringent requirements, designed to ensure the safety, efficacy, and quality of medical devices sold in Europe.

Injections

Injections Medical Portfolios Branding

Inside the Apogee Pipeline: Company Shares Updates on APG777 and APG990 for AD

The Dermatology Digest

DECEMBER 5, 2024

Apogee Therapeutics recently hosted its first R&D Day, which featured updates across its entire portfolio. The post Inside the Apogee Pipeline: Company Shares Updates on APG777 and APG990 for AD appeared first on The Dermatology Digest. Stay tuned.

Portfolios

Portfolios Dermatitis Sustainability Injections

U.S. FDA Approves Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels

The Dermatology Digest

FEBRUARY 13, 2025

This milestone represents an exciting new chapter in our long-term strategy to expand our portfolio and transition from a single-product company to a multi-product innovator, strengthening our leadership in performance beauty, says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. s Evolyssecollection.

Injections

Injections Portfolios Safety Innovations

ESK-001 Update: Alumis, Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for the TYK2 Inhibitor in Japan

The Dermatology Digest

MARCH 27, 2025

have entered into a collaboration and licensing agreement to develop, manufacture, and commercialize ESK-001, a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for dermatology indications in Japan, with the option to expand the license to include rheumatological and gastrointestinal diseases. Alumis Inc.

Pharmaceutical

Pharmaceutical Portfolios Clinic Safety

U.S. FDA Accepts sNDA for Arcutis’ Roflumilast Cream 0.05% (Zoryve) for Children Aged 2 to 5 with Mild-to-moderate AD; PDUFA Date Set

The Dermatology Digest

FEBRUARY 26, 2025

The data highlight the efficacy of the cream, along with its favorable safety and tolerability profile, which are critical when prescribing a long-term treatment for children with AD, says Mercedes E. In clinical trials, investigational ZORYVE cream 0.05% has shown significant positive results in treating AD in children 2 to 5 years old.

Safety

Safety Dermatitis Portfolios Clinic

U.S. FDA Approves Celltrion’s STELARA Biosimilar

FDA Nod for PYZCHIVA (ustekinumab-ttwe), Samsung Bioepis’ Stelara Biosimilar

PHysicians & the esthetician

FDA Approves JUVÉDERM VOLUMA XC for Filling Temple Hollows

TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology in the U.S. and Abroad

FDA Nod for Ustekinumab Biosimilar

Topline Phase 1 Trial Results for Apogee’s APG777 in AD “Exceed Expectations”

Sunscreen E-Summit 2022: Replay

2023 Sunscreen E-Summit Replay

FDA OKs Emergent’s mPox Vaccine

Evolus Scores EU Approval of Estyme Injectable Hyaluronic Acid Gel Fillers Under New Medical Device Regulation Process

Inside the Apogee Pipeline: Company Shares Updates on APG777 and APG990 for AD

U.S. FDA Approves Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels

ESK-001 Update: Alumis, Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for the TYK2 Inhibitor in Japan

U.S. FDA Accepts sNDA for Arcutis’ Roflumilast Cream 0.05% (Zoryve) for Children Aged 2 to 5 with Mild-to-moderate AD; PDUFA Date Set

Stay Connected